This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will Teladoc (TDOC) Q1 Earnings Buoy On Severe Flu Season?
by Zacks Equity Research
We expect Teladoc's (TDOC) earnings to see an upside from the recent severe flu season,which should lead to higher patient visits.
Why Is Teladoc (TDOC) Up 10.3% Since Its Last Earnings Report?
by Zacks Equity Research
Teladoc (TDOC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Teladoc (TDOC) Stock Has More Than Doubled in a Year
by Zacks Equity Research
Teladoc (TDOC) continues to gain from high demand for its telehealth services.
Teladoc (TDOC) Q4 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Teladoc (TDOC) earnings were aided by membership growth and increased visits.
Can Revenue Rise Aid Envision Healthcare (EVHC) Q4 Earnings?
by Zacks Equity Research
Envision Healthcare (EVHC) Q4 earnings might see an upside from higher revenues in Physician Services segment, partly offset by high expenses and lower revenues from Ambulatory Service segment.
Will Higher Revenues Buoy Teladoc's (TDOC) Q4 Earnings?
by Zacks Equity Research
Teladoc's (TDOC) fourth-quarter 2017 results to benefit from an increase in members utilizing its services, higher visits and growing client roaster.
Will Lower Volume Hurt Tenet Healthcare's (THC) Q4 Earnings?
by Zacks Equity Research
Industry-wide softness in admissions might affect Tenet Healthcare's (THC) fourth-quarter results.
Teladoc Provides Strong Preliminary Results & 2018 Outlook
by Zacks Equity Research
Teladoc's (TDOC) impressive fourth-quarter preliminary results and 2018 guidance reflects the company's solid business growth.
Why Teladoc (TDOC) Is Up More Than 110% So Far This Year
by Zacks Equity Research
Teladoc (TDOC) stock seems to be favored by its rapidly growing revenue base and leadership position in underpenetrated telehealth services industry.
Teladoc, Inc. (TDOC) Jumps: Stock Rises 10.5%
by Zacks Equity Research
Teladoc, Inc. (TDOC) was a big mover last session, as the company saw its shares nearly 11/% on the day amid huge volumes.
Teladoc Rides on Growing Demand for Telehealth Services
by Zacks Equity Research
Rising demand for telehealth services is likely to create long-term growth opportunities for Teladoc's (TDOC).
Teladoc (TDOC) Q3 Loss Wider Than Expected, Revenues Top
by Zacks Equity Research
Teladoc's (TDOC) third-quarter revenues grew year over year on higher visits.
Will Increased Visits Drive Teladoc's (TDOC) Q3 Earnings?
by Zacks Equity Research
Teladoc's (TDOC) earnings will benefit from its premier consumer engagement capabilities, broad network and scalable platform, which will increase visits and clients.
Will High Costs Dent Envision Healthcare (EVHC) Q3 Earnings?
by Zacks Equity Research
Envision Healthcare's (EVHC) third-quarter earnings are likely to see a drag from high expenses, partly offset by increased revenues from its physician services segment.
Will Lower Health Care Revenues Mar Aetna (AET) Q3 Earnings?
by Zacks Equity Research
Aetna's (AET) third-quarter earnings are likely see a drain from lesser membership and low revenues in the Health Care segment, partly offset by benefits from share buyback and cost control.
Will Higher Admissions Aid HCA Healthcare (HCA) Q3 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) third-quarter earnings are likely to be benefited by its inorganic growth measures partly offset by industry weakness.
Can Admissions Rise Fuel Universal Health (UHS) Q3 Earnings?
by Zacks Equity Research
Universal Health's (UHS) third-quarter results are likely to be driven by solid revenue growth in both its Acute Care and Behavioral Health segments.
Can Enrollment Growth Drive Anthem (ANTM) in Q3 Earnings?
by Zacks Equity Research
Anthem's (ANTM) third-quarter results are likely to be aided by membership growth.
Can Medicaid Business Drive Centene's (CNC) Q3 Earnings?
by Zacks Equity Research
Centene's (CNC) third-quarter results are expected to be positively impacted by its Medicaid expansion initiatives.
Teladoc (TDOC) Looks Good: Stock Adds 6.8% in Session
by Zacks Equity Research
Teladoc (TDOC) was a big mover last session, as the company saw its shares rise nearly 7% on the day amid huge volumes.
Why Is Teladoc (TDOC) Up 3.2% Since the Last Earnings Report?
by Zacks Equity Research
Teladoc (TDOC) reported earnings more than a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Teladoc (TDOC) Continues to Suffer From High Operating Cost
by Zacks Equity Research
Teladoc's (TDOC) high expenses continue to bother. Investment expenses undertaken for business growth offer no respite on this account.
Teladoc (TDOC) Q2 Loss Wider than Expected, Revenues Up Y/Y
by Zacks Equity Research
Teladoc's (TDOC) second-quarter loss was wider than expected due to higher expenses.
Healthcare Q2 Earnings Due on Aug 2: HUM, PRXL, MOH, TDOC
by Zacks Equity Research
The Medical sector is likely to benefit from inorganic growth, product launches, technology upgrades. However, regulatory hassles might offset its growth potential.
Will Teladoc (TDOC) Pull Off a Surprise in Q2 Earnings?
by Zacks Equity Research
Teladoc's (TDOC) second-quarter earnings may be driven by higher revenues and increased membership, partly offset by an increase in operating expenses.